Literature DB >> 30327756

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.

Kartik Sehgal1, Rushad Patell1, Deepa Rangachari1, Daniel B Costa1.   

Abstract

Entities:  

Year:  2018        PMID： 30327756      PMCID： PMC6186457          DOI： 10.21037/tcr.2018.08.11

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  23 in total

1.  ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.

Authors:  Jessica J Lin; Lauren L Ritterhouse; Siraj M Ali; Mark Bailey; Alexa B Schrock; Justin F Gainor; Lorin A Ferris; Mari Mino-Kenudson; Vincent A Miller; Anthony J Iafrate; Jochen K Lennerz; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2017-01-11       Impact factor: 15.609

2.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

Review 4.  Recent Advances in Targeting ROS1 in Lung Cancer.

Authors:  Jessica J Lin; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2017-08-14       Impact factor: 15.609

Review 5.  Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Authors:  Meghan Shea; Daniel B Costa; Deepa Rangachari
Journal:  Ther Adv Respir Dis       Date:  2015-11-30       Impact factor: 4.031

6.  Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Authors:  Scott N Gettinger; Lyudmila A Bazhenova; Corey J Langer; Ravi Salgia; Kathryn A Gold; Rafael Rosell; Alice T Shaw; Glen J Weiss; Meera Tugnait; Narayana I Narasimhan; David J Dorer; David Kerstein; Victor M Rivera; Timothy Clackson; Frank G Haluska; David Ross Camidge
Journal:  Lancet Oncol       Date:  2016-11-08       Impact factor: 41.316

Review 7.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

8.  Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.

Authors:  Yen-Fu Chen; Min-Shu Hsieh; Shang-Gin Wu; Yih-Leong Chang; Chong-Jen Yu; James Chih-Hsin Yang; Pan-Chyr Yang; Jin-Yuan Shih
Journal:  J Thorac Oncol       Date:  2016-04-16       Impact factor: 15.609

9.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

10.  Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Authors:  Alice T Shaw; Enriqueta Felip; Todd M Bauer; Benjamin Besse; Alejandro Navarro; Sophie Postel-Vinay; Justin F Gainor; Melissa Johnson; Jorg Dietrich; Leonard P James; Jill S Clancy; Joseph Chen; Jean-François Martini; Antonello Abbattista; Benjamin J Solomon
Journal:  Lancet Oncol       Date:  2017-10-23       Impact factor: 41.316
View more
  12 in total

Review 1.  A pharmacological exploration of targeted drug therapy in non-small cell lung cancer.

Authors:  Ajay P Jayan; K R Anandu; Krishnadas Madhu; V N Saiprabha
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

Review 2.  The state of the art for artificial intelligence in lung digital pathology.

Authors:  Vidya Sankar Viswanathan; Paula Toro; Germán Corredor; Sanjay Mukhopadhyay; Anant Madabhushi
Journal:  J Pathol       Date:  2022-06-20       Impact factor: 9.883

3.  White Blood Cell Count and Risk of Incident Lung Cancer in the UK Biobank.

Authors:  Jason Y Y Wong; Bryan A Bassig; Erikka Loftfield; Wei Hu; Neal D Freedman; Bu-Tian Ji; Paul Elliott; Debra T Silverman; Stephen J Chanock; Nathaniel Rothman; Qing Lan
Journal:  JNCI Cancer Spectr       Date:  2019-12-12

Review 4.  Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.

Authors:  Natalia Magdalena Chrzanowska; Janusz Kowalewski; Marzena Anna Lewandowska
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

5.  Comprehensive transcriptome profiling of Taiwanese colorectal cancer implicates an ethnic basis for pathogenesis.

Authors:  Shao-Min Wu; Wen-Sy Tsai; Sum-Fu Chiang; Yi-Hsuan Lai; Chung-Pei Ma; Jian-Hua Wang; Jiarong Lin; Pei-Shan Lu; Chia-Yu Yang; Bertrand Chin-Ming Tan; Hsuan Liu
Journal:  Sci Rep       Date:  2020-03-11       Impact factor: 4.379

6.  Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.

Authors:  Nahla A Mobark; Musa Alharbi; Lamees Alhabeeb; Latifa AlMubarak; Rasha Alaljelaify; Mariam AlSaeed; Amal Almutairi; Fatmah Alqubaishi; Maqsood Ahmad; Ayman Al-Banyan; Fahad E Alotabi; Duna Barakeh; Malak AlZahrani; Hisham Al-Khalidi; Abdulrazag Ajlan; Lori A Ramkissoon; Shakti H Ramkissoon; Malak Abedalthagafi
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

7.  Mining potentially actionable kinase gene fusions in cancer cell lines with the KuNG FU database.

Authors:  Alessio Somaschini; Sebastiano Di Bella; Carlo Cusi; Laura Raddrizzani; Antonella Leone; Giovanni Carapezza; Tommaso Mazza; Antonella Isacchi; Roberta Bosotti
Journal:  Sci Data       Date:  2020-11-30       Impact factor: 6.444

Review 8.  ROS1 Targeted Therapies: Current Status.

Authors:  Christine M Azelby; Mandy R Sakamoto; Daniel W Bowles
Journal:  Curr Oncol Rep       Date:  2021-06-14       Impact factor: 5.075

9.  Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.

Authors:  Yu Wang; Zheng Chen; Xiao Han; Jiamei Li; Honglin Guo; Junping Shi
Journal:  Oncologist       Date:  2020-10-28

Review 10.  Treatment of Rare Mutations in Patients with Lung Cancer.

Authors:  Tarek Taha; Rasha Khoury; Ronen Brenner; Haitam Nasrallah; Irena Shofaniyeh; Samih Yousef; Abed Agbarya
Journal:  Biomedicines       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.